Small molecule · Inhibitor of phosphatidylinositol 3-kinase delta (PI3Kd) (PIK3CD) · developed by Hutchmed
Amdizalisib (HMPL-689) is an orally bioavailable, selective inhibitor of the delta isoform of phosphatidylinositide 3-kinase (PI3Kd). It binds PI3Kd and blocks PI3Kd/AKT signaling and B-cell activation, reducing proliferation and inducing cell death in PI3Kd-overexpressing tumor cells. It is studied in relapsed or refractory lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05713110 | Phase 2 | Relapsed/Refractory Lymphoma | Completed | HCM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Relapsed/Refractory Lymphoma
Updated Oct 18, 2026. Something wrong or missing? Report it on the HCM page.
See HCM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HCM catalysts and pipeline →